Physician profile
Jonathan Willis
NPI 1437538162
$12,153.97
in general payments reported to CMS, 2019-2025
38 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $1,550 · 2021: $2,337 · 2022: $1,846 · 2023: $2,181 · 2024: $1,941 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,683.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,318.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,173.00 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,165.37 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $1,032.01 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $937.28 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $750.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.33 | 2020-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $546.65 | 2020-2025 | |
| Pfizer INC. | $518.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $468.32 | 2019-2024 | Gardasil 9, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.92 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $370.22 | 2024-2025 | Gemtesa |
| Amarin Pharma, INC. | $350.20 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $289.21 | 2022 | |
| Exact Sciences Corporation | $224.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $222.44 | 2020-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $212.10 | 2019-2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $210.27 | 2022-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $188.27 | 2024-2025 | Voquezna |
| Abbott Laboratories | $144.32 | 2021-2023 | Freestyle Libre 3 |
| Allergan, INC. | $132.39 | 2020-2021 | |
| Esperion Therapeutics, INC. | $117.16 | 2020-2023 | Nexletol |
| Genentech USA, INC. | $108.00 | 2019-2022 | |
| Nevro Corp. | $83.69 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $81.29 | 2021-2022 | |
| Corium, LLC | $67.22 | 2023-2024 | Azstarys |
| Novartis Pharmaceuticals Corporation | $52.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.42 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $36.39 | 2021-2022 | |
| Dexcom, INC. | $35.03 | 2021-2025 | Dexcom G6 Transmitter |
| Organon LLC | $33.14 | 2024 | |
| Eisai INC. | $30.47 | 2020 | |
| Coastal Medical Technologies LLC | $30.35 | 2023 | |
| Sanofi Pasteur INC. | $21.34 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.82 | 2021 | |
| Dynavax Technologies Corporation | $16.43 | 2025 | Heplisav-B |
| Lundbeck LLC | $14.87 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.